Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Interest & Investment Income (2020 - 2022)

Terns Pharmaceuticals (TERN) has disclosed Interest & Investment Income for 4 consecutive years, with $3.3 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Interest & Investment Income rose 150.98% year-over-year to $3.3 million, compared with a TTM value of $8.6 million through Dec 2023, up 309.48%, and an annual FY2023 reading of $12.9 million, up 511.42% over the prior year.
  • Interest & Investment Income was $3.3 million for Q4 2023 at Terns Pharmaceuticals, down from $3.5 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.5 million in Q3 2023 and bottomed at $1000.0 in Q3 2020.
  • Average Interest & Investment Income over 4 years is $653428.6, with a median of $55000.0 recorded in 2021.
  • Peak annual rise in Interest & Investment Income hit 4800.0% in 2021, while the deepest fall reached 78.0% in 2021.
  • Year by year, Interest & Investment Income stood at $2000.0 in 2020, then skyrocketed by 2650.0% to $55000.0 in 2021, then surged by 2314.55% to $1.3 million in 2022, then skyrocketed by 150.98% to $3.3 million in 2023.
  • Business Quant data shows Interest & Investment Income for TERN at $3.3 million in Q4 2023, $3.5 million in Q3 2023, and $1.3 million in Q4 2022.